EC
RVNC

EntryPoint Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

EntryPoint Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,906
Closed -$97.9K – 1740
2024
Q1 		$97.9K Buy
19,906
+10,400
+109% +$61.6K 0.09% 433
2023
Q4 		$83.6K Buy
+9,506
New +$77.9K 0.08% 471

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EntryPoint Capital's RVNC Position: Q2 2024 in Review

EntryPoint Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 19,906 shares — an estimated $97.9K sold.

EntryPoint Capital first reported a position in RVNC in Q4 2023 and held it in 2 quarters. The position peaked at $97.9K in Q1 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • EntryPoint Capital reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 19,906 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $97.9K.
  • EntryPoint Capital first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Revance Therapeutics, Inc. position peaked at $97.9K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.